Release effect of epirubicin hydrochloride nano-targeted delivery

doi:10.3969/j.issn.2095-4344.2013.21.007

Abstract

Abstract:

BACKGROUND: Epirubicin hydrochloride is a kind of broad-spectrum antibiotics, and the disadvantages in the clinical application are faster drug release and low drug concentrations of target tissue. Epirubicin hydrochloride can widely distribute in various organs after intravenous administration with obvious side effects.
OBJECTIVE: To prepare the epirubicin hydrochloride nano-targeted delivery according to the shortages of epirubicin hydrochloride in the clinical application.
METHODS: The epirubicin hydrochloride nano-targeted delivery was prepared with the carrier of folate-conjugated epirubicin hydrochloride albumin nanoparticles by the method of emulsification-high pressure homogenization. Particles size, distribution and Zeta potential were detected by laser particle size analyzer. The morphology of epirubicin hydrochloride nanoparticles was observed by scanning electron microscope．In addition, encapsulation capability, loading content and drug release of the folate-conjugated epirubicin hydrochloride albumin nanoparticles were analyzed by high-performance liquid chromatography．
RESULTS AND CONCLUSION: The results showed that the nanoparticles were spherical and well distributed. The mean particle size was (157.73±0.4) nm, and mean Zeta potential was (-30.85±0.43) mV. The encapsulation efficiency was 96.24% and the loading content was 22.78%. The results of simulate drug releasing results showed that the drug release curve could be divided into two phases, microspheres release in the burst release phase could reach 42.6% at 24 hours, nanoparticles release could be lasted for a long time in the sustained-release stage, and the drug release could reach to 84.1% at 112 hours. The drug release rate of the drug-loaded nanoparticles remained stable. The epirubicin hydrochloride nano-targeted delivery prepared with emulsification-high pressure homogenization has uniform particle size, narrow size distribution, high encapsulation efficiency and loading content, and has certain release effect.

Key words: biomaterials, nanobiomaterials, epirubicin hydrochloride, bovine serum album, floate, target delivery, nanoparticles, emulsification-high pressure homogenization technique, releasing in vitro, other grants-supported paper

CLC Number:

R318

Tang Jia-ming, Zhao Xiu-hua, Zu Yuan-gang. Release effect of epirubicin hydrochloride nano-targeted delivery[J]. Chinese Journal of Tissue Engineering Research, doi: 10.3969/j.issn.2095-4344.2013.21.007.

Figures/Tables 6

References

[1] J PM,Angelo DL,Marc B,et al. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer.J Clin Oncol.2001;19(12): 3103-3110.

[2] Le YL,Ho CT,Tsai FL. Inhibit multidrug resistance and induce apoptosis by using glycocholic acid and epirubicin. Eur J Pharm Sci .2008;35(1-2):52-67.

[3] Leucuta SE,Achim M,Risca R,et al.Preparation and pharmaceutical/pharmacokinetic characterization of liposomes and nanoparticles loaded with epirubicin. STP Pharma Sci. 2003;13(5):291-297.

[4] Temming K,Meyer DL,Zabinski R,et al. Evaluation of RGD-targeted albumin carriers for specific delivery of auristatin e to tumor blood vessels. Bioconj Chem .2006; 17(6): 1385-1394.

[5] Guo W,Lee RJ.Receptor-targeted gene delivery viafolate-conjugated polyethylenimine.AAPS Pharm Sci.1999;1(4):20-26. doi: 10.1208/ps010419.

[6] Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines : physiologic and clinical implications.Cancer.1994;73(9):2432-2443.

[7] Luten J,van Steenbergen MJ,Lok MC,et al.Degradable PEG-folate coated poly(DMAEA-co-BA)phosphazene-based polyplexes exhibit receptor-specific gene expression．Eur J Pharm Sci．2008;33(3):241-251.

[8] Liang B,He ML,Xiao ZP,et al.Synthesis and characterization of folate-PEG-grafted-hyperbranched-PEI for tumor-targeted gene delivery．Biochem Biophys Res Commun.2008;367(4): 874-880.

[9] Liu K,Wang K,Huang FS.Zhongguo Yaoye. 2005;14(2):46-48.刘凯,王昆,黄复生.前列腺素E1脂质体的制备及稳定性初步研究成果[J].中国药业,2005,14(2):46-48.

[10] Lee RJ,Low PS.Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis.J Biol Chem. 1994; 269(5):3198-204.

[11] Weber C,Kreuter J,Langer K,et al.Desolvation process and surface characteristics of HSA-nanoparticles.Int J Pharm. 2000;196(2):197-200.

[12] Zhang LK,Hou SX,Lu Y,et al.Zhongguo Yaoxue Zazhi. 2007；42(9):676-678.张良珂,侯世祥,卢懿,等.叶酸受体介导米托蒽醌白蛋白纳米粒的体内分布及药效学研究[J]．中国药学杂志,2007,42(9)：676-678.

[13] Xiao SR,Tong CY,Liu XM,et al.Kexue Tongbao. 2006；51(10)：1151-1155.肖苏尧,童春义,刘选明.等.肿瘤靶向性药物载体叶酸-淀粉纳米颗粒的研制与应用[J].科学通报,2006,51(10):1151-1155.

[14] Guo LY,Yao JP,Sui LH.Gaodeng Xuexiao Huaxue Xuebao. 2009;30(3):474-477.郭莉媛,姚晶萍,隋丽华.白藜芦醇白蛋白纳米粒的制备及其抗卵巢癌细胞增殖作用的研究[J].高等学校化学学报,2009,30(3)：474-477.

[15] Yang Y.Jinri Yaoxue. 2009;19(6):57-60.杨莹.硫鸟嘌呤白蛋白纳米粒的制备[J].今日药学,2009,19(6)：57-60.

[16] Wu SL,Huang JG,Li G.Zhongguo Yiyuan Yaoxue Zazhi. 2009；29(7):l522-525.伍三兰,黄建耿,李高.氟尿嘧啶白蛋白磁亚微球的制备及释药特性[J].中国医院药学杂志,2009,29(7)：522-525.